These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19567132)

  • 21. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
    Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
    J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab is active as a single agent against recurrent malignant gliomas.
    Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
    Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irradiation and bevacizumab in high-grade glioma retreatment settings.
    Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
    Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
    Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
    Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic therapy in malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Curr Opin Oncol; 2008 Nov; 20(6):652-61. PubMed ID: 18841047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
    Torcuator R; Zuniga R; Loutfi R; Mikkelsen T
    J Neurooncol; 2009 Jul; 93(3):409-12. PubMed ID: 19139822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
    Pope WB; Lai A; Nghiemphu P; Mischel P; Cloughesy TF
    Neurology; 2006 Apr; 66(8):1258-60. PubMed ID: 16636248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
    Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
    Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
    Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
    Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase I inhibitors for the treatment of brain tumors.
    Feun L; Savaraj N
    Expert Rev Anticancer Ther; 2008 May; 8(5):707-16. PubMed ID: 18471044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
    Xu T; Chen J; Lu Y; Wolff JE
    BMC Cancer; 2010 Jun; 10():252. PubMed ID: 20525214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
    Nowosielski M; Recheis W; Goebel G; Güler O; Tinkhauser G; Kostron H; Schocke M; Gotwald T; Stockhammer G; Hutterer M
    Neuroradiology; 2011 Apr; 53(4):291-302. PubMed ID: 21125399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
    Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
    J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC; Johnston S
    Cancer; 2009 Apr; 115(8):1734-43. PubMed ID: 19197992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
    Zustovich F; Lombardi G; Pastorelli D; Farina P; Furini L; Manara R; Dalla Palma M; Rotilio A; Nicoletto O; Zagonel V
    Anticancer Res; 2010 Dec; 30(12):5213-6. PubMed ID: 21187515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.